Navigation Links
Over 50% of U.S. News & World Report's "Best Heart Hospitals" Are Certified to Implant the SynCardia Total Artificial Heart
Date:8/8/2013

TUCSON, Ariz., Aug. 8, 2013 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that over half of the top 50 centers honored in U.S. News & World Report's "Best Hospitals" list for cardiology and heart surgery for 2013-2014, offer the SynCardia temporary Total Artificial Heart.

(Photo: http://photos.prnewswire.com/prnh/20130808/LA60897)

"The fact that these top U.S. transplant centers offer the SynCardia Total Artificial Heart demonstrates its growing acceptance as the new standard of care for end-stage biventricular heart failure," said Michael Garippa, SynCardia CEO and President.

In June, U.S. News and World Report published its annual list of "Best Children's Hospitals" for cardiology and heart surgery. Among the top 10 were seven pediatric centers that offer the SynCardia Total Artificial Heart: #2 Children's Hospital of Philadelphia (CHOP), #3 Texas Children's Hospital, #5 Cincinnati Children's Hospital Medical Center, #11 Children's Hospital of Wisconsin, #26 Mattel Children's Hospital UCLA, #32 Shands Hospital for Children at the University of Florida and #34 Phoenix Children's Hospital.

As of July 18, SynCardia Certified Centers worldwide have performed a record-breaking 100 implants of the SynCardia Total Artificial Heart in 2013. This milestone was achieved three months earlier than in 2012, when the 100th implant was performed on Oct. 16. Worldwide, there have been more than 1,200 implants of the Total Artificial Heart, accounting for more than 315 patient years of life.

There are currently 87 SynCardia Certified Centers worldwide, including 48 in the U.S. An additional 33 centers are currently completing SynCardia's four-phase certification program.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,200 implants of the Total Artificial Heart, accounting for more than 315 patient years of life on the device.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that eliminates the symptoms and source of end-stage biventricular failure.

The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"

In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.

For up-to-date information, please visit: http://www.syncardia.com
Like SynCardia on Facebook - http://www.facebook.com/pages/SynCardia-Systems-Inc/191245900926019
Follow SynCardia on Twitter – http://twitter.com/SynCardia


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CPhI Pharma Evolution Hosts Live Chat on How to Optimize Processes & Reduce Costs, Featuring API & Process Design Expert
2. Cardiac Monitoring & Cardiac Rhythm Management Market Report With Global Forecasts to 2017 - Market Worth $18.4 Billion in 2012
3. BC Technical Acquires C&G Technologies
4. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
5. Frost & Sullivan Analyzes Emerging Opportunities for Stakeholders in the Transforming Healthcare Industry
6. U.S. Orthopedic Biomaterials Market & Global Biomaterials Industry Reviewed by Products and Applications in New Research Reports
7. Medical Power Supply Market by Technology, Type & Application - Forecasts to 2017
8. Henry Schein Chairman Of The Board & CEO Receives Centennial Recognition Award For Extraordinary Commitment To The National Dental Association
9. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
10. Frost & Sullivan Finds the Entrenched Nature of qPCR Technology Sustains the US Reagents Market
11. Grant & Eisenhofer Represents Whistleblowers in Justice Dept. $257 Million Civil Settlement with Wyeth over Unlawful Marketing of Rapamune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
Breaking Medicine News(10 mins):